The Hourly View for MRK
Last Updated February 12, 2021, 12:47 GMT
At the moment, MRK’s price is down $-0.31 (-0.41%) from the hour prior. The hourly chart shows that MRK has seen 2 straight up hours. Regarding the trend, note that the strongest trend exists on the 100 hour timeframe. The moving averages on the hourly timeframe suggest a choppiness in price, as the are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.
Merck & Co Inc Daily Price Recap
Merck & Co Inc came into today down 0.2% ($0.15) from the open of yesterday, marking the 2nd consecutive day a decrease has occurred. This move happened on lower volume, as yesterday’s volume was down 24.99% from the day before — and down 11% from the same day the week before. Let’s take a look at the daily price chart of Merck & Co Inc.
Merck & Co Inc Technical Analysis
The clearest trend exists on the 14 day timeframe, which shows price moving down over that time. Also of note is that on a 90 day basis price appears to be forming a base — which could the stage for it being a support/resistance level going forward. For additional context, note that price has gone down 7 out of the past 10 days. Also, candlestick traders! Note we see pin bar pattern appearing here as well.
Overheard Around the Web
Over on StockTwits, here’s an example of what they’re saying about MRK:
$CERT Fellow investors $JNJ, $PFE, $MRK, CERT is an undiscovered stock. Certara is the leader in its industry, effectively the standard, benchmark, 800-pound gorilla. Profitable before even going public, this company has an all-star management team of proven veterans who earned their stripes in a who's who of top bio-pharma related companies, similar to the management team of Schrödinger $SDGR in many ways. Do your investment account a favor and consider taking a position here, it will thank you later. The stock remains “undiscovered” and still well below where it will be by EOY. Do your own DD, but here's a start.
Certara, which isn’t a biotech, provides biosimulation software to create virtual trials that use virtual patients to predict how drugs behave in different people. Its platform is used by more than 1,600 biopharmaceutical companies and academic institutions across 60 countries, including all of the top 35 biopharmaceutical companies (company prospectus).